Literature DB >> 1653278

Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages.

R C Hubbard1, G Fells, J Gadek, S Pacholok, J Humes, R G Crystal.   

Abstract

The emphysema of alpha 1-antitrypsin (alpha 1AT) deficiency is conceptualized to result from insufficient alpha 1AT allowing neutrophil elastase to destroy lung parenchyma. In addition to the deficiency of alpha 1AT in these individuals resulting from mutations in the alpha 1AT gene, it is recognized that, for unknown reasons, there are also increased numbers of neutrophils in their lungs compared with normal individuals. With the knowledge that alveolar macrophages have surface receptors for neutrophil elastase, we hypothesized that the neutrophil accumulation in the lower respiratory tract in alpha 1AT deficiency may result, in part, from release of neutrophil chemotactic activity by alveolar macrophages as they bind uninhibited neutrophil elastase. Consistent with this hypothesis, alpha 1AT-deficient alveolar macrophages spontaneously released nearly threefold more neutrophil chemotactic activity than normal alveolar macrophages. Analysis of alpha 1AT-deficient macrophage supernates by reverse-phase HPLC, molecular sieve chromatography, radioimmunoassay, and absorption with anti-LTB4 antibody revealed that the majority of the chemotactic activity was leukotriene B4 (LTB4), a mediator absent from normal macrophage supernates. Consistent with this hypothesis, incubation of normal macrophages with human neutrophil elastase resulted in the release of the same neutrophil chemotactic mediator. Furthermore, purified human alpha 1AT was able to prevent the neutrophil elastase from stimulating the macrophages to release the chemotactic factor. Together, these findings suggest that the absence of a normal antineutrophil elastase screen in the lower respiratory tract permits free neutrophil elastase to bind to alveolar macrophages, resulting in the release of LTB4, a process which attracts neutrophils to the alveoli of alpha 1AT deficient individuals, thus accelerating the lung destruction that characterizes this disorder.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653278      PMCID: PMC295476          DOI: 10.1172/JCI115391

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  55 in total

1.  Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase.

Authors:  R C Hubbard; F Ogushi; G A Fells; A M Cantin; S Jallat; M Courtney; R G Crystal
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

2.  Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema.

Authors:  M D Wewers; M A Casolaro; S E Sellers; S C Swayze; K M McPhaul; J T Wittes; R G Crystal
Journal:  N Engl J Med       Date:  1987-04-23       Impact factor: 91.245

3.  The role of complement in cigarette smoke-induced chemotactic activity of lung fluids.

Authors:  R R Kew; B Ghebrehiwet; A Janoff
Journal:  Am Rev Respir Dis       Date:  1986-03

4.  Report of Nomenclature Meeting for alpha 1-antitrypsin, INSERM, Rouen/Bois-Guillaume-1978.

Authors:  D W Cox; A M Johnson; M K Fagerhol
Journal:  Hum Genet       Date:  1980       Impact factor: 4.132

Review 5.  Human plasma proteinase inhibitors.

Authors:  J Travis; G S Salvesen
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

6.  Evaluation of the protease-antiprotease theory of human destructive lung disease.

Authors:  J E Gadek; G W Hunninghake; G A Fells; R L Zimmerman; B A Keogh; R G Crystal
Journal:  Bull Eur Physiopathol Respir       Date:  1980

7.  Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema.

Authors:  J E Gadek; G A Fells; R L Zimmerman; S I Rennard; R G Crystal
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

8.  Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin.

Authors:  K Beatty; J Bieth; J Travis
Journal:  J Biol Chem       Date:  1980-05-10       Impact factor: 5.157

9.  A comparison of the binding and fate of internalized neutrophil elastase in human monocytes and alveolar macrophages.

Authors:  S E McGowan; R D Arbeit; P J Stone; G L Snider
Journal:  Am Rev Respir Dis       Date:  1983-10

10.  Alpha 1-proteinase inhibitor is a neutrophil chemoattractant after proteolytic inactivation by macrophage elastase.

Authors:  M J Banda; A G Rice; G L Griffin; R M Senior
Journal:  J Biol Chem       Date:  1988-03-25       Impact factor: 5.157

View more
  57 in total

Review 1.  Alpha-1-antitrypsin deficiency: what next?

Authors:  R A Stockley
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

Review 2.  Factors influencing airway inflammation in chronic obstructive pulmonary disease.

Authors:  A Hill; S Gompertz; R Stockley
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

Review 3.  Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

Review 4.  Lung disease associated with alpha1-antitrypsin deficiency.

Authors:  Rubin M Tuder; Sabina M Janciauskiene; Irina Petrache
Journal:  Proc Am Thorac Soc       Date:  2010-11

Review 5.  Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease.

Authors:  Caroline A Owen
Journal:  Proc Am Thorac Soc       Date:  2005

Review 6.  COPD exacerbations . 2: aetiology.

Authors:  E Sapey; R A Stockley
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

7.  Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol.

Authors:  Charlie Strange; Robert M Senior; Frank Sciurba; Scott O'Neal; Alison Morris; Stephen R Wisniewski; Russell Bowler; Harry S Hochheiser; Michael J Becich; Yingze Zhang; Joseph K Leader; Barbara A Methé; Naftali Kaminski; Robert A Sandhaus
Journal:  Ann Am Thorac Soc       Date:  2015-10

Review 8.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

9.  Role of leukotriene A4 hydrolase aminopeptidase in the pathogenesis of emphysema.

Authors:  Mikell Paige; Kan Wang; Marie Burdick; Sunhye Park; Josiah Cha; Erin Jeffery; Nicholas Sherman; Y Michael Shim
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

10.  Exhaled leukotrienes and prostaglandins in COPD.

Authors:  P Montuschi; S A Kharitonov; G Ciabattoni; P J Barnes
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.